Skip to main content
. 2023 Mar 22;12(6):2437. doi: 10.3390/jcm12062437

Table 1.

Demographics and baseline characteristic of 22 kidney transplant recipients who underwent conversion to belatacept due to clinical indication *.

Patient Count 22
Demographics
Patient age in years (IQR) 53 (36–59)
Patient sex (female/male) 16 (73%) vs. 6 (27%)
Clinical history
Primary disease
  • -

    Glomerulonephritis

  • -

    Genetic disease

  • -

    Hypertensive or diabetic

  • -

    Interstitial nephritis

  • -

    Other

  • -

    Unknown
9 (41%)
4 (18%)
2 (9%)
2 (9%)
1 (5%)
4 (18%)
Preemptive/PD/HD 3 (14%)/5 (23%)/14 (64%)
Median time on dialysis in years (IQR) 1 (1–6.5)
Transplantation
Median years since transplantation (IQR)
Converted in the first 6 months after transplantation (n)		 9.5 (5.5–13)
2
Living vs. deceased donation
AB0-incompatible		 14 (64%) vs. 8 (36%)
4 (18%)
Median donor age in years (IQR) 55 (50–61)
Mean cold ischemia time in minutes +/− SD (for deceased donors) 725 +/− 284
Induction immunosuppression
  • -

    Basiliximab

  • -

    Rituximab + Basiliximab (for AB0-incompatible)

  • -

    Unknown
15 (68%)
2 (9%)
5 (23%)
Maintenance immunosuppression
  • -

    Tacrolimus/Cyclosporine/Sirolimus

  • -

    MPA

  • -

    Steroid
17 (77%)/4 (18%)/1 (5%)
20 (91%)
17 (77%)
Latest biopsy results before conversion (more than one can apply)
  • -

    ABMR

  • -

    ATN due to acute CNI toxicity

  • -

    ah2/ah3 as sign of chronic CNI toxicity

  • -

    No biopsy
8 (36%)
3 (14%)
1 (5%)/15 (68%)
4 (18%)

* IQR, interquartile range; SD, standard deviation; PD, peritoneal dialysis; HD, hemodialysis; MPA, mycophenolic acid; ATN, acute tubular necrosis; ah, arteriolar hyalinosis according to Banff 2017 classification; CNI, calcineurin inhibitor; ABMR, antibody-mediated rejection.